miRagen Therapeutics

Miragen Therapeutics is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their role in diseases. microRNAs are short RNA molecules, or oligonucleotides, that regulate gene expression and play vital roles in influencing the pathways responsible for several disease processes. The company has advanced two product candidates, cobomarsen, also known as MRG-106, and MRG-201, into clinical development. The company is also developing MRG-110 under a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier.
  • TickerMGEN
  • ISINUS60463E1038
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Q2 Financials And Prioritization of Pipeline Progress

1 director bought

A director at Miragen Therapeutics Inc bought 10,000 shares at 4.770USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

ValuEngine Rating and Forecast Report for MGEN

MarketLine Department

AdheraTherapeutics - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's AdheraTherapeutics Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by AdheraTherapeutics since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. K...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch